West Pharmaceutical Services (WST) has been in the limelight for various factors: ongoing lawsuits, financial performance, partnership announcements, and other events. The company has been facing several
class-action lawsuits filed by different legal firms, urging WST investors with substantial losses to contact them before the stated deadlines. The lawsuits are primarily its security fraud, bringing down its market credibility.
Bank of America continues to keep their 'Buy' rating on the company. The firm has also announced its upcoming
Q2 2025 results, which is gaining attention among investors. However, it has faced setbacks in stock performance, falling behind its competitors, and reduced its guidance. Despite this, its unexpected collaboration with
Corning on drug delivery and packaging solutions, and its Q2 performance beating Street expectations has placed it back in a favorable position. According to some views, WST seems undervalued after its recent earnings slide, positioning it as a potential investment opportunity. The company's forthcoming events also include leadership changes and Q3 2025 dividend declaration.
West Pharmaceutical Services WST News Analytics from Thu, 29 Jul 2021 07:00:00 GMT to Sat, 19 Jul 2025 15:44:11 GMT -
Rating -3
- Innovation 2
- Information 8
- Rumor -7
